ACCESS Newswire
17 Aug 2022, 22:43 GMT+10
NEW YORK, NY / ACCESSWIRE / August 17, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Molecular Partners AG (NASDAQ:MOLN)
CONTACT JAKUBOWITZ ABOUT MOLN:
https://claimyourloss.com/securities/molecular-partners-ag-loss-submission-form/?id=30951&from=1
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
Lead Plaintiff Deadline : September 12, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
TG Therapeutics, Inc. (NASDAQ:TGTX)
CONTACT JAKUBOWITZ ABOUT TGTX:
https://claimyourloss.com/securities/tg-therapeutics-inc-loss-submission-form/?id=30951&from=1
Class Period : January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline : September 16, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
Tuya Inc. (NYSE:TUYA)
CONTACT JAKUBOWITZ ABOUT TUYA:
https://claimyourloss.com/securities/tuya-inc-loss-submission-form/?id=30951&from=1
This lawsuit is on behalf of all persons or entities who purchased Tuya American Depositary Shares in or traceable to the Company's March 2021 initial public offering.
Lead Plaintiff Deadline : October 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) a material portion of Tuya's China-based customers were engaged in the widespread and systematic manipulation of reviews and product offerings in violation of Amazon.com's terms of use; (b) prior to the initial public offering, a consumer investigation and data breach had exposed an illicit fake review scheme being perpetrated by many of Tuya's clients, among others, which included, inter alia, the exposure of 13 million records of organized fake review scams linked to over 200,000 Amazon account profiles; (c) as a result of (a) and (b) above, there was a substantial risk that a material portion of Tuya's significant customers would be barred from using Amazon.com's platform, negatively impacting Tuya's business, revenue, earnings, and prospects; and (d) as a result of (a)-(c) above, the registration statement's representations regarding Tuya's historical financial and operational metrics and purported market opportunities and expected growth did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the initial public offering, and such statements were materially false and misleading and lacked a reasonable factual basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law
Get a daily dose of Atlanta Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Atlanta Leader.
More InformationDERA BAJWA, Pakistan: Amir Ali, a 21-year-old man from Pakistan, dreamed of going to Europe for a better life. He was promised a visa...
TOKYO, Japan: Japan's hopes for a foothold in commercial lunar exploration suffered a second blow this week after Tokyo-based startup...
MOSCOW, Russia: Russia's principal security agency, the Federal Security Service (FSB), has accused British intelligence of using the...
SYDNEY, Australia: Australia will not ease its strict biosecurity rules during trade talks with the United States, Prime Minister Anthony...
The Israeli Navy has intercepted a ship carrying humanitarian aid and a number of activists including Greta Thunberg, Rima Hassan,...
TOKYO, Japan: Japan's demographic challenges intensified in 2024, with the number of births falling to another all-time low—underscoring...
NEW YORK, New York - U.S. stock markets rose Tuesday as investors and traders anticipated a positive outcome from ongoing trade talks...
BEIJING/WASHINGTON, D.C.: In a rare move aimed at easing mounting supply chain pressure, China has issued temporary export licenses...
BERN, Switzerland: UBS faces a sweeping new capital requirement from the Swiss government, which this week proposed changes that could...
NEW YORK CITY, New York: At a Walmart Supercenter in New Jersey, buttercream borders and edible-ink cartoons aren't just about sweet...
NEW YORK, New York - Wall Street delivered a split performance on Monday, with the Nasdaq Composite notching up gains while the Dow...
NEW YORK CITY, New York: Luxury group Kering is in exclusive discussions to sell a stake in its prime New York real estate asset on...